ArticleCureus2022
The Risk of Non-arteritic Ischemic Optic Neuropathy Post-intravitreal Bevacizumab Injection.
Article in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 4 citations in OpenAlex.
- Systemic Effects of Intravitreal Anti-VEGF Therapy: A Review of Safety across Organ Systems.Ophthalmology and therapy · 2025Review
- Dose-Related Side Effects of Intravitreal Injections of Humanized Anti-Vascular Endothelial Growth Factor in Rats: Glial Cell Reactivity and Retinal Ganglion Cell Loss.Investigative ophthalmology & visual science · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo report the incidence of non-arteritic ischemic optic neuropathy in diabetic patients treated with intravitreal bevacizumab injection.
methodsA prospective comparative analytic study was done in the King Hussein Medical Center during the period between June 2020 and June 2021. Inclusion criteria included diabetic patients who attended a retina clinic. Exclusion criteria included patients with pre-existing ischemic optic neuropathy. Patients were divided into two groups. The first group included diabetic patients who did not require bevacizumab injection and were treated either with follow-up visits or pan-retinal photocoagulation, and the second group included patients who were treated with intravitreal bevacizumab. Patients were followed up for a period of one year. Data collected in two groups included the total number of patients and the number of patients with non-arteritic ischemic optic neuropathy. Results were compared in both groups. A P-value was used to study the statistical significance and was considered to be statistically significant if ≤0.05.
resultsThe mean age for patients in group 1 was 64.3 years, with a male to female ratio of 1.1 to 1. In group 2, the mean age was 66.2 years, with a male to female ratio of 1.2 to 1. The total number of patients in group 1 was 7375, among whom 68 patients had non-arteritic ischemic optic neuropathy. While in group 2, the total number was 2468 and 49 of them had non-arteritic ischemic optic neuropathy. Most cases of non-arteritic ischemic optic neuropathy were seen in patients who had received three or more injections. Conclusion: Intravitreal bevacizumab in diabetic patients is considered a risk factor for the development of non-arteritic ischemic optic neuropathy, especially in patients receiving more than three injections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.